All the Drug Class Drugs
Anti PD-1 Monoclonal Antibody. dostarlimab 50 mg/ml. Vial, conc. for sol. for inf. 10 ml X1
Recomm. dose is 500 mg dostarlimab every 3 weeks in combin. with carboplatin and paclitaxel every 3 weeks for 6 cycles followed by 1000 mg dostarlimab as monother. every 6 weeks for all cycles thereafter till dis. progress. or unacceptable tox., or for up to 3 years.
As monother., 500 mg dostarlimab every 3 weeks for 4 cycles followed by 1000 mg every 6 weeks for all cycles thereafter until dis. progress. or unacceptable tox.
In combin. with carboplatin and paclitaxel for adults with mismatch repair deficient (dMMR)/ microsatellite instability-high (MSI-H) primary adv. or recurrent endometrial cancer (EC) and who are candidates for syst. ther.
As monother. for adults with dMMR/MSI-H recurrent or adv. EC that has progressed on or following prior tmt. with a platinum-containing regimen.
C/I: Hypersens.
Anti PD-1 Monoclonal Antibody. tislelizumab 100 mg. Vial. Conc. for sol. for infus. 100 mg/10 ml (1 or 2 Vials)
Dose: 200 mg IV once /3 weeks.
Treat until dis. progress. or unacceptable tox.
Oesophageal sq. cell carcinoma (OSCC)
As monother. for adlts. with unresectable, locally adv. or metastatic oesophageal squamous cell carcinoma after prior platinum-based chemother.
C/I: Hypersens
